Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bluebird bio CFO Transition

This article was originally published in Scrip

Executive Summary

Bluebird Bio, Inc., a company developing therapies for genetic diseases and cancer, has appointed Jeffrey Walsh chief financial and strategy officer – effective March 1, 2016. Current chief financial officer, Jim DeTore, has decided to leave the company – effective March 18, 2016. Since 2011 Walsh was chief operating officer at bluebird bio and prior to joining the company, he was chief business officer at Taligen Therapeutics. He has held senior business development, finance and operations roles at PathoGenesis Corp., AllScripts Healthcare Solutions, EXACT Sciences and Inotek Pharmaceuticals.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel